ReviewClinical pharmacokinetics2000
Pharmacokinetic considerations in the eradication of Helicobacter pylori.
Review in Clinical pharmacokinetics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis.Medicine · 2017Pooled it
- Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.World journal of gastroenterology · 2012Pooled it
- Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.Clinical pharmacokinetics · 2005Pooled it
- A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication ofInfection and drug resistance · 2023Trial
- Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.British journal of clinical pharmacology · 2022Trial
- Evaluation of pharmacokinetic interactions of amoxicillin with ranitidine in healthy human volunteers of Karachi, Pakistan.PloS one · 2022Trial
- Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.Digestive diseases and sciences · 2005Trial
- Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-LineMicroorganisms · 2024Article
- Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics.Pharmacological reports : PR · 2023Review
- Vonoprazan and high-dose amoxicillin dual therapy forJGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Evaluating physicians' awareness and prescribing trends regarding proton pump inhibitors: a cross-sectional study.Frontiers in pharmacology · 2023Article
- 25 Years of Proton Pump Inhibitors: A Comprehensive Review.Gut and liver · 2017Review
- How May Proton Pump Inhibitors Impair Cardiovascular Health?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2016Review
- Influence of esomeprazole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits.Molecular and cellular biochemistry · 2011Article
- Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor.ACS chemical biology · 2011Article
- Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients.Clinical and experimental nephrology · 2010Article
- Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.European journal of clinical pharmacology · 2010Review
- Efficient identification and evaluation of effective Helicobacter pylori therapies.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2009Review
- Proton pump inhibitors: an update of their clinical use and pharmacokinetics.European journal of clinical pharmacology · 2008Review
- New concepts of resistance in the treatment of Helicobacter pylori infections.Nature clinical practice. Gastroenterology & hepatology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As Helicobacter pylori plays an important role in the aetiopathogenesis of peptic ulcer, therapeutic strategies aimed at maintaining long term remission have shifted from the control of intragastric pH to targeting H. pylori. According to recent international guidelines the clinical goals--rapid ulcer healing and prevention of relapse--can be best accomplished by combination therapy consisting of an antisecretory drug (proton pump inhibitor or ranitidine) and 2 antimicrobial agents (preferable amoxicillin, clarithromycin or metronidazole). When applying such multidrug regimens, possible synergy between the agents suggests that pharmacokinetic considerations might help to improve H. pylori eradication rates, which should be above 85 to 90% on an intention-to-treat basis. The present review summarises the pharmacokinetic properties and interaction potential of all drugs presently used in the various H. pylori eradication regimens, with emphasis on particular patient populations such as the elderly and those with renal impairment. The drugs considered are omeprazole, lansoprazole, pantoprazole, rabeprazole, ranitidine and ranitidine bismutrex, bismuth salts, amoxicillin, clarithromycin, azithromycin, roxithromycin, metronidazole, tinidazole and tetracycline. When addressing the clinically important questions of the efficacy, safety and costs of the recommended regimens, the impact of drug disposition on H. pylori eradication should not be neglected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.